- See Also
-
Links
- “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity”, Malhotra et al 2024
- “Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
- “Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial”, Wadden et al 2023
- “A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
- “Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): a Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial”, Garvey et al 2023
- “Lilly's Tirzepatide Achieved up to 15.7% Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2”, Lilly 2023
- “Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): a Double-Blind, Multicentre, Randomized, Phase 3 Trial”, Inagaki et al 2022
- “Tirzepatide Once Weekly for the Treatment of Obesity”, Jastreboff et al 2022
- “FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Lilly 2022
- “Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, Lilly & Company 2022
- “Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Dahl et al 2022
- “Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
- “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, Prato et al 2021
- “Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec As Add-On to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomized, Open-Label, Parallel-Group, Phase 3 Trial”, Ludvik et al 2021
- “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Frías et al 2021
- “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-Blind, Randomized, Phase 3 Trial”, Rosenstock et al 2021
- “Society Is Fixed, Biology Is Mutable”
- Sort By Magic
- Wikipedia
- Miscellaneous
- Link Bibliography
See Also
Links
“Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity”, Malhotra et al 2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
“Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
“Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial”, Wadden et al 2023
“A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
“Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): a Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial”, Garvey et al 2023
“Lilly's Tirzepatide Achieved up to 15.7% Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2”, Lilly 2023
“Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): a Double-Blind, Multicentre, Randomized, Phase 3 Trial”, Inagaki et al 2022
“Tirzepatide Once Weekly for the Treatment of Obesity”, Jastreboff et al 2022
“FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Lilly 2022
“Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, Lilly & Company 2022
“Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Dahl et al 2022
“Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
“Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, Prato et al 2021
“Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec As Add-On to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomized, Open-Label, Parallel-Group, Phase 3 Trial”, Ludvik et al 2021
“Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Frías et al 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]
“Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-Blind, Randomized, Phase 3 Trial”, Rosenstock et al 2021
“Society Is Fixed, Biology Is Mutable”
Sort By Magic
Annotations sorted by machine learning into inferred 'tags'. This provides an alternative way to browse: instead of by date order, one can browse in topic order. The 'sorted' list has been automatically clustered into multiple sections & auto-labeled for easier browsing.
Beginning with the newest annotation, it uses the embedding of each annotation to attempt to create a list of nearest-neighbor annotations, creating a progression of topics. For more details, see the link.
tirzepatide-obesity
tirzepatide-trials
GLP-1-agonist
Wikipedia
Miscellaneous
Link Bibliography
-
2023-lingvay.pdf: “A Revolution in Obesity Treatment”, -
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and: “FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, -
2021-delprato.pdf: “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, -
2021-frias.pdf: “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”,